Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer
Kanda M, Kasahara Y, Shimizu D, Miwa T, Umeda S, Sawaki K, Nakamura S, Kodera Y, Obika S. Mol Ther Nucleic Acids. 2020 Oct 6;22:791-802. Pubmed
Designing siRNAs for improving their therapeutic applications
Presenter: Dr. Annabelle Biscans (AstraZeneca) Date: January 27th, 2021 Description: Small interfering RNAs (siRNAs) have the potential to revolutionize medicine due to their potency, duration of effect, and ability to target previously “undruggable” disease genes. The clinical success of siRNAs is dependent on their ...
Making medicines out of pre-mRNA splicing modulators
Presenter: Isabel Aznarez, Ph.D. Stoke Therapeutics Date: April 29th, 2021 Description: Splicing is the process that edits precursor-messenger RNA (pre-mRNA) to generate the messenger RNA (mRNA) that carries the code from the nucleus to the cytoplasm where the ribosomes will translate it into a ...
20th Anniversary of RNA Interference in Mammalian Cells
The groundbreaking discovery of RNA interference by Craig Mello and Andrew Fire was swiftly followed by the discovery of RNAi as a gene-silencing mechanism in mammalian cells. Since these breakthroughs, members of our community have devoted their lives to building on these exciting discoveries, ...
October 2020 Paper of the Month
The chromosomal 2q21.3 locus has undergone positive selection in the last 5000 years in Europeans and this has long been attributed to the presence of the lactase gene.
Oligonucleotides and the OTS Community Provide Excellent Solutions to the COVID-19 Pandemic
Oligonucleotide therapies are relatively new in the field of medicine, but they have allowed us to make astounding progress in the fight against COVID-19. Rather than simply repurposing existing drugs or spending years to develop new drugs and vaccines, oligo therapies are quickly providing ...
